STOCK TITAN

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags

Cytokinetics (NASDAQ: CYTK) has announced the recipients of its seventh annual Communications Grant Program, awarding a total of $100,000 to five patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure communities. Each organization received $20,000 to support communications, awareness building, and community engagement initiatives.

The 2025 grant recipients include AICARM APS (Italian Association of Cardiomyopathies), HeartBrothers Foundation, HeartCharged , Hypertrophic Cardiomyopathy Association (HCMA), and Stichting Cardiomyopathie Onderzoek Nederland. The funds will support various projects including educational video production, patient quality of life assessments, short films about HCM patient experiences, digital partnerships, and qualitative research to improve patient and healthcare professional engagement.

Cytokinetics (NASDAQ: CYTK) ha annunciato i destinatari del suo settimo programma annuale di sovvenzioni per la comunicazione, assegnando un totale di 100.000 dollari a cinque organizzazioni di advocacy dei pazienti focalizzate su cardiomiopatia ipertrofica (HCM) e comunità di insufficienza cardiaca. Ogni organizzazione ha ricevuto 20.000 dollari per supportare le iniziative di comunicazione, sensibilizzazione e coinvolgimento della comunità.

I destinatari delle sovvenzioni del 2025 includono AICARM APS (Associazione Italiana delle Cardiomiopatie), Fondazione HeartBrothers, HeartCharged, Associazione per la Cardiomiopatia Ipertrofica (HCMA) e Stichting Cardiomyopathie Onderzoek Nederland. I fondi sosterranno vari progetti tra cui la produzione di video educativi, valutazioni della qualità della vita dei pazienti, cortometraggi sulle esperienze dei pazienti con HCM, partnership digitali e ricerche qualitative per migliorare il coinvolgimento dei pazienti e dei professionisti sanitari.

Cytokinetics (NASDAQ: CYTK) ha anunciado los beneficiarios de su séptimo programa anual de subvenciones de comunicación, otorgando un total de 100,000 dólares a cinco organizaciones de defensa de los pacientes enfocadas en la cardiomiopatía hipertrófica (HCM) y comunidades de insuficiencia cardíaca. Cada organización recibió 20,000 dólares para apoyar iniciativas de comunicación, sensibilización y participación comunitaria.

Los beneficiarios de la subvención 2025 incluyen AICARM APS (Asociación Italiana de Cardiomiopatías), Fundación HeartBrothers, HeartCharged, Asociación de Cardiomiopatía Hipertrófica (HCMA) y Stichting Cardiomyopathie Onderzoek Nederland. Los fondos apoyarán diversos proyectos, incluyendo la producción de videos educativos, evaluaciones de calidad de vida de los pacientes, cortometrajes sobre las experiencias de los pacientes con HCM, asociaciones digitales y estudios cualitativos para mejorar el compromiso de los pacientes y los profesionales de la salud.

Cytokinetics (NASDAQ: CYTK)는 제7회 연례 커뮤니케이션 보조금 프로그램 수혜자를 발표하였으며, 심비대성심근병증(HCM)과 심부전 커뮤니티에 초점을 맞춘 5개의 환자 옹호 단체에 총 100,000 달러를 수여하였습니다. 각 단체는 커뮤니케이션, 인식 제고 및 지역사회 참여 이니셔티브를 지원하기 위해 20,000 달러를 받았습니다.

2025년도 보조금 수혜자는 AICARM APS(이탈리아 심근병증 협회), HeartBrothers 재단, HeartCharged, 심비대성심근병증협회(HCMA), 그리고 Stichting Cardiomyopathie Onderzoek Nederland입니다. 이 자금은 교육 비디오 제작, 환자 삶의 질 평가, HCM 환자 경험에 관한 단편 영화, 디지털 파트너십 및 환자와 의료 전문가의 참여를 개선하기 위한 질적 연구 등 다양한 프로젝트를 지원합니다.

Cytokinetics (NASDAQ: CYTK) a annoncé les bénéficiaires de son septième programme annuel de subventions en communication, attribuant un total de 100 000 $ à cinq organisations de plaidoyer pour patients axées sur la cardiomyopathie hypertrophique (HCM) et les communautés de défaillance cardiaque. Chaque organisation a reçu 20 000 $ pour soutenir des initiatives de communication, de sensibilisation et d'engagement communautaire.

Les bénéficiaires de la subvention 2025 incluent AICARM APS (Association Italienne des Cardiomyopathies), la Fondation HeartBrothers, HeartCharged, l'Association de Cardiomyopathie Hypertrophique (HCMA) et Stichting Cardiomyopathie Onderzoek Nederland. Les fonds soutiendront divers projets, notamment la production de vidéos éducatives, des évaluations de la qualité de vie des patients, des courts métrages sur les expériences des patients atteints de HCM, des partenariats numériques et des recherches qualitatives pour améliorer l'engagement des patients et des professionnels de la santé.

Cytokinetics (NASDAQ: CYTK) hat die Empfänger seines siebten jährlichen Kommunikationszuschussprogramms bekannt gegeben und insgesamt 100.000 USD an fünf Patientenvertretungsorganisationen vergeben, die sich auf hypertrophe Kardiomyopathie (HCM) und Herzinsuffizienz-Communities konzentrieren. Jede Organisation erhielt 20.000 USD, um Kommunikations-, Sensibilisierungs- und Gemeindeengagement-Initiativen zu unterstützen.

Zu den Zuschussempfängern 2025 gehören AICARM APS (Italienische Vereinigung der Kardiomyopathien), HeartBrothers Foundation, HeartCharged, die Hypertrophic Cardiomyopathy Association (HCMA) und Stichting Cardiomyopathie Onderzoek Nederland. Die Mittel werden verschiedene Projekte unterstützen, darunter die Produktion von Bildungsvideos, Bewertungen der Lebensqualität von Patienten, Kurzfilme über die Erfahrungen von HCM-Patienten, digitale Partnerschaften und qualitative Forschung zur Verbesserung des Engagements von Patienten und Gesundheitsfachkräften.

Positive
  • None.
Negative
  • None.

Total of $100,000 Awarded to Five Patient Advocacy Organizations
to Support Communications and Community Outreach

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program, intended to support increased communications, awareness building and community engagement.

Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) and heart failure communities. The grants will support these organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement.

“We are pleased to announce this year’s recipients of the Cytokinetics Communications Grant Program, each of whom has demonstrated creativity and vision in addressing communication challenges to expand awareness and engagement in the HCM and heart failure patient communities they serve,” said Mary Pomerantz, Cytokinetics’ Senior Director of Patient Advocacy and Engagement. “Together, these grants will play a pivotal role in advancing initiatives to increase diagnosis of cardiovascular conditions, educate patients and their families about available resources and provide comprehensive support to improve overall health and well-being.”

The recipients of the 2025 Cytokinetics Communications Grants include:

AICARM APS (Italian Association of Cardiomyopathies): AICARM APS is an Italian non-profit organization composed of volunteers, patients, doctors and nurses that provides support to patients with cardiomyopathy and their families, promotes training and the dissemination of scientific information and supports scientific research of cardiomyopathies. With the grant, AICARM APS will produce a series of five videos to be featured on their website, highlighting essential topics such as updated guidelines for managing cardiomyopathies, the importance of genetic testing and family screening and advancements in new disease-specific therapies. The grant will also support the development of QualyHCM, a questionnaire for patients and physicians, developed by patients and physicians, to assess the quality of life of patients with HCM.

HeartBrothers Foundation: The HeartBrothers Foundation is a non-profit organization dedicated to helping patients with heart failure and their families navigate the complex journey of heart failure, mechanical circulatory support and heart transplantation. HeartBrothers will use the grant to grow digital and in-person partnerships with regional heart failure hospitals in New England, refine advertising and communication segmentations and develop content.

HeartCharged Corporation: HeartCharged Corporation is a charitable organization with global reach whose mission is ending preventable deaths from sudden cardiac arrest and undiagnosed heart conditions and providing patient-to-patient support. HeartCharged will use this grant to create a short form dramatized film centered around the life choices of a young person living with HCM, serving as a discussion starter on the social and mental health challenges faced by young patients. In addition to producing the film, the grant will support accompanying promotional materials and educational resources.

Hypertrophic Cardiomyopathy Association: The Hypertrophic Cardiomyopathy Association (HCMA) is a non-profit organization that provides support, advocacy and education to patients, families, the medical community and the public about HCM while also supporting the research and development of potential HCM treatments. With this grant, HCMA will develop a short film about the patient journey in HCM, touching on the difficulties of diagnosis to the everyday challenges of living with HCM. The grant will also support the distribution, publicity and partnership planning around the film.

Stichting Cardiomyopathie Onderzoek Nederland (Foundation Cardiomyopathy Research the Netherlands): Stichting Cardiomyopathie Onderzoek Nederland is a non-profit foundation that collaborates with research institutes, hospitals and other organizations and stakeholders involved in scientific research in the field of congenital and genetic heart disease. With the funding, Stichting Cardiomyopathie Onderzoek Nederland will conduct qualitative research through individual interviews and focus groups to inform communication and education strategies to improve engagement with patients and healthcare professionals.

About the Cytokinetics Communications Grant Program

For the past seven years, the Cytokinetics Communications Grant Program has supported patient advocacy organizations to help expand their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Cytokinetics has no oversight, involvement or management of the actual projects, programs or outputs. The goal of the Communications Grant Program is to assist patient advocacy organizations by increasing resources in order to better support patient communities and bring increased disease awareness in the communities they serve. The call for proposals for the 2026 Communications Grant Program will be announced during Fall 2025.

About Cytokinetics

Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757


FAQ

How much did Cytokinetics (CYTK) award in its 2025 Communications Grant Program?

Cytokinetics awarded a total of $100,000, with $20,000 given to each of the five recipient organizations.

Which organizations received CYTK's 2025 Communications Grants?

The recipients were AICARM APS, HeartBrothers Foundation, HeartCharged , Hypertrophic Cardiomyopathy Association (HCMA), and Stichting Cardiomyopathie Onderzoek Nederland.

What is the purpose of Cytokinetics' Communications Grant Program?

The program supports increased communications, awareness building, and community engagement for patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) and heart failure communities.

How will AICARM APS use its CYTK grant funding?

AICARM APS will produce five educational videos and develop QualyHCM, a questionnaire to assess the quality of life of HCM patients.

Cytokinetics Inc

NASDAQ:CYTK

CYTK Rankings

CYTK Latest News

CYTK Stock Data

6.03B
114.81M
0.54%
119.33%
11.89%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO